AU541321B2 - Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives - Google Patents

Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives

Info

Publication number
AU541321B2
AU541321B2 AU16416/83A AU1641683A AU541321B2 AU 541321 B2 AU541321 B2 AU 541321B2 AU 16416/83 A AU16416/83 A AU 16416/83A AU 1641683 A AU1641683 A AU 1641683A AU 541321 B2 AU541321 B2 AU 541321B2
Authority
AU
Australia
Prior art keywords
antibodies
related derivatives
labeled conjugates
digoxigenin
immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16416/83A
Other languages
English (en)
Other versions
AU1641683A (en
Inventor
James Paul Albarella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Publication of AU1641683A publication Critical patent/AU1641683A/en
Application granted granted Critical
Publication of AU541321B2 publication Critical patent/AU541321B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AU16416/83A 1982-09-23 1983-06-30 Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives Ceased AU541321B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/422,217 US4469797A (en) 1982-09-23 1982-09-23 Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US422217 1982-09-23

Publications (2)

Publication Number Publication Date
AU1641683A AU1641683A (en) 1984-03-29
AU541321B2 true AU541321B2 (en) 1985-01-03

Family

ID=23673888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16416/83A Ceased AU541321B2 (en) 1982-09-23 1983-06-30 Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives

Country Status (8)

Country Link
US (1) US4469797A (enExample)
EP (1) EP0104527B1 (enExample)
JP (1) JPS5983056A (enExample)
AU (1) AU541321B2 (enExample)
CA (1) CA1213579A (enExample)
DE (1) DE3369887D1 (enExample)
ES (1) ES525861A0 (enExample)
IL (1) IL69126A0 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588219B2 (en) * 1983-08-16 1989-09-14 Agence Nationale De Valorisation De La Recherche (Anvar) Derivatives of muramyl-peptides and of steroids having macrophage-activating properties

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650771A (en) * 1983-11-04 1987-03-17 Miles Laboratories, Inc. Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
US4595656A (en) * 1984-01-06 1986-06-17 Becton Dickinson & Company Coupling agents and products produced therefrom
US4654311A (en) * 1984-06-15 1987-03-31 Syntex (U.S.A.) Inc. Serum pretreatment for digoxin assay
US4767720A (en) * 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
FR2601141A1 (fr) * 1986-07-02 1988-01-08 Centre Nat Rech Scient Produit de couplage a base d'haptene, utile notamment comme substance immunogene, anticorps correspondants et applications
US5034317A (en) * 1987-01-30 1991-07-23 Polaroid Corporation Enzyme controlled release system and organic conjugate reactant
US6326136B1 (en) * 1988-04-01 2001-12-04 Digene Corporation Macromolecular conjugate made using unsaturated aldehydes
DE3836656A1 (de) * 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
CA2031109C (en) * 1990-07-27 1992-01-28 Susan J. Danielson Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
RU2132553C1 (ru) * 1996-05-30 1999-06-27 Ивановская Елена Алексеевна Количественное определение дигоксина в сыворотке крови методом инверсионной вольтамперометрии
WO1998036099A1 (en) * 1997-02-18 1998-08-20 Oncor, Inc. Detection of targets with green fluorescent protein and fluorescent variants thereof
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
KR20020018197A (ko) * 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP5390055B2 (ja) 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
ATE492565T1 (de) * 2002-01-31 2011-01-15 Randox Lab Ltd Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US7935539B2 (en) * 2003-02-14 2011-05-03 Siemens Healthcare Diagnostics, Inc. Generic method for latex agglutination assays
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2005172694A (ja) * 2003-12-12 2005-06-30 Fuji Photo Film Co Ltd タンパク質の検出方法
PT1699822E (pt) * 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
RU2503463C2 (ru) 2006-07-03 2014-01-10 Чарльз Дэвид ЭДЕЙР Композиция для модулирования экспрессии молекул клеточной адгезии
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
ES2731432T3 (es) * 2007-05-23 2019-11-15 Ventana Med Syst Inc Transportadores poliméricos para inmunohistoquímica e hibridación in situ
DK2995925T3 (da) 2008-06-05 2022-02-21 Ventana Med Syst Inc Sammensætning til histokemisk processering
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
SG175233A1 (en) * 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
JP2013531801A (ja) 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
CA2822481A1 (en) * 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
CA2842971C (en) 2011-08-05 2019-11-12 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
RU2743169C2 (ru) 2015-11-06 2021-02-15 Вентана Медикал Системз, Инк. Репрезентативная диагностика
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
KR102367074B1 (ko) 2016-03-29 2022-02-25 주식회사 에스티큐브 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
US20200290978A1 (en) 2017-09-26 2020-09-17 The Regents Of The University Of California Compositions and methods for treating cancer
EP3710820B1 (en) 2017-11-13 2025-06-11 F. Hoffmann-La Roche AG Devices for sample analysis using epitachophoresis
JP7455816B2 (ja) * 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
CN110174363A (zh) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953431A (en) * 1971-05-24 1976-04-27 Becton, Dickinson & Company Derivatives of digoxigenin
US3855208A (en) * 1971-05-24 1974-12-17 Becton Dickinson Co Derivatives of digoxigenin
GB1441101A (en) * 1972-06-22 1976-06-30 Wellcome Found Reagents for the assay of cardenolide glycosides and aglycones
US4064227A (en) * 1975-03-17 1977-12-20 Mallinckrodt, Inc. Radioimmunoassay method for the determination of cardiotonic glycosides
FR2310766A1 (fr) * 1975-05-16 1976-12-10 Nativelle Sa Ets Derives de cardenolides, procede de preparation et application a titre de medicament
US4082747A (en) * 1975-10-01 1978-04-04 Mallinckrodt, Inc. Chemical process
JPS53119873A (en) * 1977-03-28 1978-10-19 Rohm & Haas Digoxigenin derivative
CA1119163A (en) * 1977-09-01 1982-03-02 Ravi K. Varma Digoxigenin derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588219B2 (en) * 1983-08-16 1989-09-14 Agence Nationale De Valorisation De La Recherche (Anvar) Derivatives of muramyl-peptides and of steroids having macrophage-activating properties

Also Published As

Publication number Publication date
IL69126A0 (en) 1983-10-31
CA1213579A (en) 1986-11-04
DE3369887D1 (en) 1987-04-02
ES8601478A1 (es) 1985-11-01
AU1641683A (en) 1984-03-29
US4469797A (en) 1984-09-04
JPS5983056A (ja) 1984-05-14
ES525861A0 (es) 1985-11-01
EP0104527A1 (en) 1984-04-04
JPH0231346B2 (enExample) 1990-07-12
EP0104527B1 (en) 1987-02-25

Similar Documents

Publication Publication Date Title
AU1641683A (en) Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives
AU589635B2 (en) Antibody conjugates
AU2060283A (en) Alpha-aryl-1h-azolyl-1-ethanol derivatives
AU554345B2 (en) Tricyclic antidepressant drug immunogens, antibodies labelled conjugates, and related derivatives
AU590462B2 (en) Immunoglobulin conjugates
AU2589984A (en) Galactosyl-insulin conjugates
AU541679B2 (en) Ergolinyl -n:,n:-diethylurea derivatives
AU7334987A (en) Immunoglobulin conjugates
AU572792B2 (en) 2-amino, 4-oxo-pteridine derivatives
AU2274783A (en) Pyridine derivatives
DE3471756D1 (en) Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
AU2222083A (en) Pyridine derivatives
AU1800483A (en) Desoxyuridine derivatives
AU566419B2 (en) U/,3-oxazoliding-2-one derivatives
AU563950B2 (en) 2,2 -disubstituted-1,3-oxepine derivatives
AU1288188A (en) Immunoglobulin conjugates
AU4724385A (en) Elektrodanordning for vattenrenare enligt jonisations- principen, foretradesvis for simbassanger
AU1575383A (en) 1,4-dihyropyridine derivatives
AU565538B2 (en) 3,3-dialkyl indoline derivatives
AU1867883A (en) Sulfamoylbenzophenone derivatives
AU568295B2 (en) 1,2,4-triazol-i-yl-propionitrile derivatives
AU534679B2 (en) Steroid immunogens
AU2277283A (en) Pyridyloxybenzanilide derivatives
AU544710B2 (en) Disopyramide immunogens, antibodies and labelled conjugates
AU556771B2 (en) Cyclohexeny pyridine derivatives